Serum APN/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer.
Serum APN/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer.
复制标题
血清 APN/CD13 作为胰腺癌的新型诊断和预后生物标志物
DOI：
10.18632/oncotarget.12835
复制
发表时间：
2016-11-22
期刊：
影响因子：
--
通讯作者：
Meng X
中科院分区：
文献类型：
--
作者：
Pang L;Zhang N;Xia Y;Wang D;Wang G;Meng X
氨肽酶N，也称为CD 13，已被报道在几种癌症中过表达，并可能有助于肿瘤转移和血管生成。本研究旨在探讨血清APN/CD 13是否可作为胰腺癌诊断和预后的潜在生物标志物。检测了382例胰腺炎患者血清APN/CD 13和糖链抗原19-9（CA 19 -9）水平，其中PC组204例，良性胰腺肿瘤组（BPT）48例，慢性胰腺炎组（CP）43例，健康对照组（HC）87例。我们使用受试者工作特征（ROC）分析来计算诊断准确性。研究血清APN/CD 13水平与PC患者临床病理特征及其生存期的关系。血清APN/CD 13水平在PC患者明显高于对照组。ROC曲线分析显示APN/CD 13在鉴别PC与对照组方面明显优于CA 19 -9。早期PC也观察到类似结果。此外，与单独使用APN/CD 13和CA 19 -9数据相比，联合使用APN/CD 13和CA 19 -9数据提高了PC与对照组的诊断准确性。血清APN/CD 13水平与肿瘤大小、淋巴结转移和TNM分期有关。多因素分析和ROC曲线分析显示，血清APN/CD 13水平升高是预测死亡率和总生存期的独立因素。Kaplan-Meier分析显示，血清APN/CD 13水平升高与OS呈负相关。本研究证实，血清APN/CD 13可能是PC诊断和预后的新生物标志物。
Aminopeptidase N, also known as CD13, has been reported to be overexpressed in several cancers and may contribute to tumor metastasis and angiogenesis. The aim of this study was to evaluate whether serum APN/CD13 could be a potential biomarker for the diagnosis and prognosis of pancreatic cancer (PC). Serum APN/CD13 and carbohydrate antigen 19-9 (CA19-9) levels were measured from 382 participants, which comprised of 204 participants with PC, 48 participants with benign pancreatic tumors (BPT), 43 participants with chronic pancreatitis (CP) and 87 healthy controls (HC). We used receiver operating characteristic (ROC) analysis to calculate diagnostic accuracy. The association of serum APN/CD13 levels with the clinicopathological characteristics of PC patients and their survival was investigated. Serum APN/CD13 levels were substantially higher in PC patients than in controls. ROC analysis revealed that APN/CD13 was significantly better than CA19-9 in differentiating patients with PC from controls. Similar results were noted for early-stage PC. Moreover, the combined use of APN/CD13 and CA19-9 data improved the diagnostic accuracy for PC vs. controls, compared with either test alone. High serum APN/CD13 levels were associated with tumor size, lymph nodes, and metastasis (TNM) stage. Multivariate and ROC curve analyses revealed that high serum APN/CD13 level is an independent factor for predicting mortality and overall survival (OS). Moreover, Kaplan–Meier analysis demonstrated an inverse correlation between increased serum APN/CD13 level and OS. Our study established that serum APN/CD13 may be a novel diagnostic and prognostic biomarker for PC.